Učitavanje...
The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin
Sodium glucose co-transporter (SGLT-2) inhibitor is a relatively new medication used to treat diabetes. At present, the Food and Drug Administration (FDA) has only approved three medications (canagliflozin, dapagliflozin and empagliflozin) in this drug class for the management of Type 2 diabetes. In...
Spremljeno u:
| Izdano u: | Oxf Med Case Reports |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4962888/ https://ncbi.nlm.nih.gov/pubmed/27471597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/omcr/omw061 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|